Tarsus Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Securities Trading Plans of Directors and Executive Officers
In December 2024, Bobak Azamian, our Chief Executive Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 24,000 shares of common stock held by Dr. Azamian between March 24, 2025 and March 23, 2026. For the quarter ended September 30, 2025, Dr. Azamian sold 12,000 shares under this adopted 10b5-1 Plan.
In September 2025, Dianne Whitfield, our Chief Human Resources Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 57,925 shares of common stock held by Ms. Whitfield between December 16, 2025 and April 1, 2026.
In September 2025, William Link, a member of our Board of Directors, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 50,000 shares of common stock held by Dr. Link between December 15, 2025 and December 14, 2026.
During the quarter ended September 30, 2025, none of our other officers or directors, as defined in Rule 16a-1(f), informed us of anadoption ortermination of a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, each as defined in Regulation S-K Item 408.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.